Full-Time

Director – Statistical methodology and Innovation

Confirmed live in the last 24 hours

Deadline 9/6/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Compensation Overview

$216.6k - $262.4k/yr

+ Incentive Cash + Stock Opportunities

Expert

Company Historically Provides H1B Sponsorship

Princeton, NJ, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Ph.D. in Statistics/Biostatistics with 9+ years of experience in Pharmaceutical RD or academia/government
  • Solid understanding of drug development with proven track record of leading statistical innovation
  • Deep expertise in one of the following scientific topics (with proven publication records) and working knowledge of the others: Bayesian Methods, Adaptive Design, RWE, Advanced Predictive Modelling, Survival Analysis, Decision Analysis
  • Ability to summarize technically/analytically complex information for a non-technical audience
  • Demonstrated ability to work in a team environment with good interpersonal, communication, writing and organizational skills
  • Ability to organize multiple work assignments and establish priorities.
Responsibilities
  • Drives formulation, development and implementation of innovative novel statistical analysis methods and innovative study designs across therapeutic areas.
  • Facilitates discussions translates scientific questions into statistical terms and statistical concepts into layman terms.
  • Influences stakeholders by communicating effectively the findings of their project-driven research to cross-functional teams; provides interpretation of their scientific results in a manner accessible to non-statisticians.
  • Functions as statistical lead on statistical topics influencing and advising senior leadership on issues that have business impact.
  • Continually develops technical knowledge of statistical methodology and build BMS external scientific reputation via publications and presentations.
  • Continually enhances their knowledge of drug development process, regulatory and commercial requirement.
  • Develops more junior stat methodologists by providing mentorship and coaching as well as developing training curriculum for the broader GBDS organization.
  • Effectively communicates the GBDS Mission and Vision in a fashion that generates pride, excitement and commitment within GBDS.
  • Enables a culture of inclusiveness, respect for diversity, compliance with process and allows for the questioning and challenging of others in a respectful and constructive manner.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are then sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet the same quality and safety standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, as well as its commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing access to effective and affordable healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with BioNTech could lead to breakthroughs in cancer immunotherapy.
  • Commitment to $40 billion US investment shows focus on long-term growth and innovation.
  • Collaboration with Tubulis may expand BMS's oncology portfolio with targeted therapies.

What critics are saying

  • Recent layoffs may disrupt operations and affect employee morale.
  • $11.1 billion BioNTech partnership could strain finances if outcomes are unsuccessful.
  • Reliance on real-world data requires consistent, scalable data quality approaches.

What makes Bristol Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company invests heavily in R&D to create new drugs and therapies.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

Hit Consultant
Jun 10th, 2025
From Raw Records To Real-Time Insights: Climbing Pharma’S Real-World Data Maturity Curve

Viraj Narayanan, CEO at Cornerstone AI Daniel Lane, Head of RWD Strategy & Operations at Bristol Myers SquibbReal-world data (RWD) has become the pharmaceutical industry’s most promising yet challenging frontier. While companies have long recognized its potential to complement clinical trials and deepen patient outcome insights, many still struggle to fully realize its value.We’ve seen firsthand, from early discovery to market authorization to post-launch evidence generation, that extracting meaningful value from RWD requires more than just data acquisition. It demands a consistent, scalable, and repeatable approach to data quality, as well as a strategic roadmap that moves an organization from minimal use of RWD to a position of true leadership. This journey isn’t simple, but for those committed to navigating it, the competitive advantages are substantial. And, importantly, RWD holds the potential to help bring lifesaving and life-changing medications to market faster and safer than ever before.From Data Collection to MaturityPharma’s growing reliance on RWD has encouraged an influx of partnerships with data aggregators, medical institutions, and digital health platforms. Yet, not all companies are at the same level of maturity in using that data effectively

Devdiscourse
Jun 2nd, 2025
Reuters Health News Summary

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could take on rival Merck & Co's best-selling drug Keytruda.

The Motley Fool
Jun 2nd, 2025
Why BioNTech Stock Soared Today

BioNTech and Bristol Myers Squibb are teaming up to develop a new cancer drug, BNT327.

Pharmaceutical Executive
Jun 2nd, 2025
Bristol Myers Squibb, BioNTech Partner to Develop Next-Gen Bispecific Antibody for Solid Tumors

Bristol Myers Squibb, BioNTech partner to develop next-gen Bispecific Antibody for solid tumors.

PRWeb
May 30th, 2025
The Melanoma Research Foundation To Host The Denver Miles For Melanoma 5K

The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we will be hosting our annual Denver event on Saturday, June 14, 2025 at Sloan Lake Park at 7:30 AM MT. Opening Ceremonies will start at 8:30 AM MT and our race will kick off promptly at 9:00 AM MT. We are excited to share that Kyle Speller, PA Announcer for the Denver Nuggets, will be returning as our emcee on event day! We're also excited to welcome back local sponsor, Cara Mia Dermatology, who will be providing free on-site skin screenings—helping our community stay sun-safe while supporting a great cause.DENVER, May 29, 2025 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we will be hosting our annual Denver event on Saturday, June 14, 2025 at Sloan Lake Park at 7:30 AM MT. Opening Ceremonies will start at 8:30 AM MT and our race will kick off promptly at 9:00 AM MT